In this episode of Moving Medicine Forward, host Jeremy Schrand welcomes Dr. Rich Curry to discuss how CTI is helping redefine what’s possible in clinical research. From the complexities of cell and gene therapy to the human stories behind the science, Dr. Curry shares how CTI’s expertise in rare diseases and regenerative medicine is accelerating innovation and improving patient outcomes. Discover how CTI’s patient-first approach and global regulatory insight are shaping the future of advanced therapies.

01:03 Dr. Curry explains how his background in neuropsychology and oncology research led him to clinical trials and CTI. 

03:08 Dr. Curry highlights why cell and gene therapy excites him, emphasizing its potential to transform treatment approaches. 

04:20 He explains how CTI’s full-service research model supports complex, high-risk cell and gene therapy trials. 

05:39 Dr. Curry describes the critical safety considerations in cell and gene therapy trials, particularly around immune system risks. 

09:31 He explains how CTI approaches long-term follow-up and risk mitigation, sometimes monitoring patients for up to 15 years. 

10:51 Dr. Curry shares how CTI stays ahead of global regulatory expectations through its dedicated regulatory and scientific affairs team. 

12:03 He gives an example of how CTI helped a sponsor overcome regulatory challenges by identifying risk factors to ensure trial continuation. 

13:16 Dr. Curry explains how CTI’s focus on regenerative medicine and rare disease expertise sets it apart in gene therapy support. 

14:01 He discusses how CTI’s patient-first philosophy shapes trial design to improve patient experience and trial success. 

14:54 Dr. Curry shares excitement for future innovations, especially in treating solid tumors, autoimmune diseases, and neurodegenerative disorders. 

17:00 He explains how CTI prepares for the next wave of therapies by building strong sponsor partnerships and providing excellent service.